 | Drug Safety Update MHRA July-2020-DSU-PDF.pdf (203KB) | 31/07/2020 | Download |
| | Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection. Liposomal and lipid-complex formulations: name change to reduce medication errors | |
| Drug Safety Update MHRA June-2020-DSU-PDF.pdf (286KB) | 29/06/2020 | Download |
| | | |
| Drug Safety Update MHRA May-2020-DSU.pdf (244KB) | 21/05/2020 | Download |
| | | |
| Drug Safety Update MHRA April-2020 PDF.pdf (194KB) | 28/04/2020 | Download |
| | | |
| Drug Safety Update MHRA March-2020-PDF.pdf (301KB) | 07/04/2020 | Download |
| | Esmya - licence suspended: tofacitinib [Xeljanz] - new measures to minimise risk of VTE & of serious and fatal infections: Baricitinib - risk of venous thromboembolism | |
| Drug Safety Update MHRA Feb-2020-PDF.pdf (337KB) | 13/02/2020 | Download |
| | Ingenol mebutate gel (Picato▼): suspension of the licence due to risk of skin malignancy. Lemtrada▼ (alemtuzumab): updated restrictions and strengthened monitoring requirements following review of... | |
| Drug Safety Update MHRA Jan-2020-PDF-final.pdf (261KB) | 29/01/2020 | Download |
| | E-cigarettes use or vaping - reporting suspected adverse reactions, including lung injury: Ondansetron - small increased risk of oral clefts following use in the first 12 weeks of pregnancy.... | |
| Drug Safety Update MHRA December 2019 PDF.pdf (201KB) | 18/12/2019 | Download |
| | Domperidone for nausea and vomiting: lack of efficacy in children: reminder of contraindications in adults and adolescents | |
| Drug Safety Update MHRA November 2019-PDF.pdf (252KB) | 22/11/2019 | Download |
| | Yellow fever vaccine: Carfilzomib (Kyprolis▼): risk of reactivation of hepatitis B virus: | |
| Drug Safety Update MHRA October 2019 PDF.pdf (336KB) | 23/10/2019 | Download |
| | Ingenol mebutate gel (Picato▼): increased incidence of skin tumours seen in some clinical studies. Nivolumab (Opdivo): reports of cytomegalovirus (CMV) gastrointestinal infection or reactivation.... | |
| Drug Safety Update MHRA September 2019 PDF.pdf (291KB) | 23/09/2019 | Download |
| | | |
| Drug Safety Update MHRA July 2019 PDF.pdf (398KB) | 18/07/2019 | Download |
| | Febuxostat (Adenuric): increased risk of cardiovascular death and all-cause mortality in clinical trial in patients with a history of major cardiovascular disease. Tocilizumab (RoActemra): rare risk... | |
